Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.

"Conflict of interest The authors declare no conflict of interest."

"This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines []. It is also registered in PROSPERO (http://www.crd.york.ac.uk/prospero) with registration number CRD 42023407550. We extracted the following information: reference of study, study design, country, intervention details, outcome measures, and Clinical Trial Identifier. Efficacy outcomes included: improvement in EASI from baseline, the proportion of patients achieving IGA response from baseline (IGA = 0 [clear] or IGA = 1 [almost clear]), change from baseline in peak NRS scores, the proportion of patients who had achieved at least a 75% improvement in EASI score from baseline (EASI-75). Safety outcomes included AEs and SAEs."